Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

IGF-1 LR3 vs MGF

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

This combination is flagged

Two IGF-1 analogs in the same regimen: Moderate-High risk per peptide research literature. Multiple IGF-1 analogs compete for the same IGF-1R pool; the second analog does not raise peak receptor activation but stacks hypoglycemia exposure, cardiac/renal/hepatic hypertrophy signal, and peripheral neuropathy risk in heavy stacks.

Data-derived verdict

IGF-1 LR3 has stronger documented evidence (Anecdotal + Animal Studies) than MGF (Preclinical + Anecdotal) while both occupy the igf-1 class. When clinical-evidence tier is the deciding factor, IGF-1 LR3 is the safer pick. MGF may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

IGF-1 LR3

Anecdotal + Animal Studies

MGF

Preclinical + Anecdotal

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

IGF-1 LR3 MGF
Class IGF-1 analog (extended half-life); anabolic IGF-1 splice variant peptide; anabolic
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism IGF-1 receptor agonist; Arg3 substitution reduces IGFBP binding for prolonged activity Local muscle IGF-1 splice variant; activates satellite cells after mechanical damage
Route SC / IM IM (localized)
Half-life ~20-30 hrs ~5-7 min
Dosage (research) 20 mcg SC daily (Seeds Vol 1 endurance and recovery starting dose, range up to 100 mcg/day for hypertrophy per r/Peptides wiki) 100-400 mcg post-workout IM into target muscle
Evidence tier Anecdotal + Animal Studies Preclinical + Anecdotal
Research depth 34 indexed (PubMed 15 · CT 0 · EPMC 19) 68 indexed (PubMed 60 · CT 0 · EPMC 8)
Availability Research Chemical Research Chemical
Reported risks Hypoglycemia risk; theoretical cancer risk; disproportional organ/tissue growth Very short half-life; injection site only; limited human data

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick IGF-1 LR3 or MGF?

IGF-1 LR3 has stronger documented evidence (Anecdotal + Animal Studies) than MGF (Preclinical + Anecdotal) while both occupy the igf-1 class. When clinical-evidence tier is the deciding factor, IGF-1 LR3 is the safer pick. MGF may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between IGF-1 LR3 and MGF?

IGF-1 LR3 is classed as IGF-1 analog (extended half-life); anabolic; MGF is classed as IGF-1 splice variant peptide; anabolic. Reported mechanism: IGF-1 LR3, IGF-1 receptor agonist; Arg3 substitution reduces IGFBP binding for prolonged activity; MGF, Local muscle IGF-1 splice variant; activates satellite cells after mechanical damage. Reported half-life: IGF-1 LR3, ~20-30 hrs; MGF, ~5-7 min. Routes in published studies: IGF-1 LR3, SC / IM; MGF, IM (localized).

Which has stronger evidence, IGF-1 LR3 or MGF?

IGF-1 LR3 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. IGF-1 LR3 is graded Anecdotal + Animal Studies, with 2 cited sources on its reference page and 34 indexed studies. MGF is graded Preclinical + Anecdotal, with 2 cited sources on its reference page and 68 indexed studies.

Which is more accessible, IGF-1 LR3 or MGF?

Neither IGF-1 LR3 nor MGF is an FDA-approved drug. Catalog status: IGF-1 LR3, Research Chemical; MGF, Research Chemical.

Are IGF-1 LR3 and MGF ever combined?

IGF-1 LR3 and MGF appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two IGF-1 analogs in the same regimen, moderate-high risk.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…